Refractory metastatic breast cancer: Salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium

J. H. Doroshow, L. Leong, K. Margolin, B. Flanagan, D. Goldberg, M. Bertrand, S. Akman, B. Carr, O. Odujinrin, E. Newman, T. Litchfield

Research output: Contribution to journalArticle

Abstract

Sixty women with metastatic breast cancer refractory to at least one chemotherapeutic regimen were treated with fluorouracil (FUra) and high-dose continuous infusion folinic acid (leucovorin calcium). One complete remission lasting 8.7 months and nine partial remissions ranging in duration from 1.3 to 12.8 months were observed, for an objective response rate of 17% (95% confidence interval for response, 8% to 27%). Nine of the ten responding patients had metastatic disease that had objectively progressed on previous chemotherapy with a FUra-containing regimen. This program was well tolerated, with toxicities consisting mainly of stomatitis and granulocytopenia. These results suggest that augmentation of the reduced folate levels of metastatic breast carcinoma may enhance the effectiveness of the fluoropyrimidines in this disease.

Original languageEnglish
Pages (from-to)439-444
Number of pages6
JournalJournal of Clinical Oncology
Volume7
Issue number4
Publication statusPublished - 1989

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Refractory metastatic breast cancer: Salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium'. Together they form a unique fingerprint.

  • Cite this

    Doroshow, J. H., Leong, L., Margolin, K., Flanagan, B., Goldberg, D., Bertrand, M., Akman, S., Carr, B., Odujinrin, O., Newman, E., & Litchfield, T. (1989). Refractory metastatic breast cancer: Salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. Journal of Clinical Oncology, 7(4), 439-444.